A post by @FirstSquawk on X.
AMGEN RAISES ITS FY GUIDANCE, NOW SEEING FY REVENUE $38.9 BLN TO $39.7 BLN FROM $38.2 BLN TO $39.4 B…
@FirstSquawk on X
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Amgen raised its full-year guidance, now projecting revenue of $38.9 billion to $39.7 billion, up from a prior range of $38.2 billion to $39.4 billion, and adjusted EPS of $22.90 to $23.70 versus $22.30 to $23.50 previously. The upward revision signals stronger-than-expected business momentum for the biopharmaceutical company. Investors will watch whether the improved outlook is sustained in upcoming quarterly results and whether pipeline or product-level details explain the raise.
Muhabbit's AI wrote this summary of @FirstSquawk's post in its own words. It can get details wrong, so read the post on X.
Named in this story
Amgen